Valion Bio Inc (VBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Valion Bio Inc (VBIO) has a cash flow conversion efficiency ratio of -0.444x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.28 Million) by net assets ($11.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Valion Bio Inc market cap and net worth for the company's overall valuation and market capitalisation.
Valion Bio Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Valion Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Valion Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valion Bio Inc ranked by their cash flow conversion efficiency. Explore Valion Bio Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Savannah Resources Plc
LSE:SAV
|
-0.033x |
|
Prostemics Co. Ltd
KQ:203690
|
-0.036x |
|
Therma Bright Inc
V:THRM
|
0.026x |
|
KINGS ENTERTAINMENT GROUP
F:L12
|
N/A |
|
RIVER TECH EO -005
F:9YQ
|
N/A |
|
Kulthorn Kirby Public Company Limited
BK:KKC
|
0.049x |
|
Mobeus Income And Growth Vct Plc
LSE:MIX
|
-0.004x |
|
Beeks Trading Corporation Ltd
LSE:BKS
|
0.143x |
Annual Cash Flow Conversion Efficiency for Valion Bio Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Valion Bio Inc from 2010 to 2025. View VBIO live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -32.17% |
| 2020-12-31 | $863.39K | $-1.61 Million | -1.859x | +33.60% |
| 2019-12-31 | $1.28 Million | $-3.59 Million | -2.800x | +68.74% |
| 2017-12-31 | $322.27K | $-2.89 Million | -8.957x | -142.16% |
| 2016-12-31 | $374.37K | $-1.38 Million | -3.699x | -213.68% |
| 2015-12-31 | $-518.16K | $-1.69 Million | 3.254x | +40.47% |
| 2014-12-31 | $-1.08 Million | $-2.50 Million | 2.316x | -88.05% |
| 2013-12-31 | $-110.00K | $-2.13 Million | 19.389x | +571.15% |
| 2012-12-31 | $-570.00K | $-1.65 Million | 2.889x | +895.44% |
| 2011-12-31 | $-90.00K | $-26.12K | 0.290x | +45899.55% |
| 2010-12-31 | $-49.99 Million | $-31.54K | 0.001x | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more